AbbVie Files New Infringement Case Over Blockbuster Drug Humira

, Delaware Law Weekly

   | 0 Comments

AbbVie Inc. filed a patent infringement lawsuit Wednesday against German rival Boehringer Ingelheim Pharmaceuticals Inc., the second case in Delaware that seeks to block sales of a less-expensive biosimilar version of Humira, AbbVie's top-selling drug.

This premium content is reserved for Delaware Law Weekly subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202794622138

Thank you!

This article's comments will be reviewed.